Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268229
Max Phase: Preclinical
Molecular Formula: C51H58F4N8O6S2
Molecular Weight: 1019.20
Associated Items:
ID: ALA5268229
Max Phase: Preclinical
Molecular Formula: C51H58F4N8O6S2
Molecular Weight: 1019.20
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCNC(=O)c2ccc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)cc2F)C(C)(C)C)cc1
Standard InChI: InChI=1S/C51H58F4N8O6S2/c1-30-42(71-29-59-30)32-16-14-31(15-17-32)27-58-45(67)40-25-36(64)28-61(40)46(68)43(49(2,3)4)60-41(65)13-11-9-7-8-10-12-22-57-44(66)37-21-20-35(24-39(37)52)63-48(70)62(47(69)50(63,5)6)34-19-18-33(26-56)38(23-34)51(53,54)55/h14-21,23-24,29,36,40,43,64H,7-13,22,25,27-28H2,1-6H3,(H,57,66)(H,58,67)(H,60,65)/t36-,40+,43-/m1/s1
Standard InChI Key: SVTIVBBIZFCGJI-QIWIAYTASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1019.20 | Molecular Weight (Monoisotopic): 1018.3857 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):